


# PlexPCR<sup>®</sup> SARS-CoV-2

Dual target COVID-19 test

Scalable solution supporting surge capacity





## Simple workflow, seamless integration

- ▶ High-throughput, compatible with 384-well and liquid handling instrumentation to accelerate time to result
- ▶ Supply chain security for high-volume testing based on unique probe chemistry technology
- ▶ Detect known circulating variants<sup>‡</sup> with confidence - conserved dual target (RdRp/ORF1ab) design for high specificity and sensitivity

# Scalable throughput with minimal equipment

Maintain clinically relevant turn-around using 96- or 384-well options

- ▶ Improve efficiency and cost-effectiveness with **PlexPrep**® automation
- ▶ 384-well format: up to **1920 samples** in 8 hrs with a single FTE<sup>s</sup>





## SpeeDx Analysis software

- ▶ Automate data processing and results interpretation for large numbers of samples simultaneously
- ▶ Speed up results processing and spend your time only on the few samples that require attention
- ▶ Automated plate set-up options for a streamlined workflow
- ▶ High security and GDPR compliant with LIS compatibility

# PlexPrep® - clever, compact robotics

Accelerate your sample preparation and qPCR set-up with the **SpeedX PlexPrep®** automation solution. Fast, precise, and easy to use, ideal for testing surges.

- ▶ Includes nimble 8+2 pipetting configuration, liquid level detection, and monitored air displacement technology for rapid and reproducible performance



- ▶ Compact system (63.5cm x 53.4cm, 41.6kg) with integrated touchscreen

- ▶ Compatible with range of primary specimen tubes, extraction consumables, and 96- and 384-well plates



## Test with confidence

- ▶ Two-target design focused on non-variable gene targets *ORF1ab* and *RdRp*, plus RNA-based Internal Control
- ▶ Conserved gene regions for excellent specificity and clinical sensitivity,<sup>¶¶</sup> unaffected by spike protein mutations and other known variants
- ▶ Full process control monitors extraction performance, RT-step and amplification for full confidence in results



**PlexPCR**<sup>®</sup> SARS-CoV-2 is a dual-target, single-well, multiplex reverse transcriptase qPCR test for the detection of COVID-19 causative coronavirus (SARS-CoV-2) plus RNA internal control.<sup>1</sup>

Powered by proprietary **PlexPCR**<sup>®</sup> technology demonstrating improved multiplex performance compared with other probe-based tests.<sup>2</sup>

| Well | Channel | Target               |
|------|---------|----------------------|
| 1    | 1       | ORF1ab               |
|      | 2       | RdRp                 |
|      | 3       | RNA Internal Control |

Validated with nasopharyngeal swab specimens.<sup>1</sup>

Demonstrated clinical performance<sup>1</sup>

| Clinical evaluation of <b>PlexPCR</b> <sup>®</sup> SARS-CoV-2 (n=142) |                                   |
|---|-----------------------------------|
| Positive Percent Agreement  | 93.26%<br>(95% CI 85.90 - 97.49%) |
| Negative Percent Agreement  | 96.23%<br>(95% CI 87.02 - 99.54%) |
| Overall Rate of Agreement   | 94.37%<br>(95% CI 89.20 - 97.54%) |

Composite reference result from Abbott m2000 SARS-CoV-2 assay & BGI real-time fluorescent RT-PCR Kit for detection of SARS-CoV-2.<sup>1</sup>

## Streamline your Respiratory testing

### **PlexPCR**<sup>®</sup> SARS-CoV-2 plus **PlexPCR**<sup>®</sup> RespiVirus

**PlexPCR**<sup>®</sup> SARS-CoV-2 workflow is compatible with **PlexPCR**<sup>®</sup> RespiVirus for a comprehensive Respiratory virus testing solution. A single extraction, combined amplification and automated analysis workflow, utilising just 3 wells for 12 results.

| Product   | Compatible     | Size  | Cat#               |
|---|----------------|---|--------------------|
| <b>PlexPCR</b> <sup>®</sup> SARS-CoV-2*         | LC480 II / CFX | 384 reactions <sup>†</sup>                  | 1301384            |
| Related Products                                | Compatible     | Size  | Cat#               |
| <b>PlexPCR</b> <sup>®</sup> RespiVirus          | LC480 II       | 100 reactions<br>192 reactions <sup>†</sup> | 1201001<br>1201192 |
| <b>PlexPrep</b> <sup>®</sup> Liquid Handler     | Enquire        | 1 unit                                      | 6600200-01         |
| <b>PlexPCR</b> <sup>®</sup> Colour Compensation | LC480 II       | 2 reactions                                 | 90001              |

\* Based on *in silico* investigation as of May 2024

§ SpeedX calculations with **PlexPrep**<sup>®</sup> Liquid Handler

ψ Contact tech@speedx.com.au for up-to-date QAP data

† Additional volumes provided for use with liquid handling systems

Available only in Australia and NZ

References: 1. **PlexPCR**<sup>®</sup> SARS-CoV-2 Instructions for use 2. Tan LY *et al*, PLOS ONE. 2017; 12(1): e0170087

**PlexPCR**<sup>®</sup> SARS-CoV-2 and RespiVirus kits are developed and manufactured by **SpeedX** Pty Ltd, Sydney. **PlexPCR**<sup>®</sup> & **SpeedX**<sup>®</sup> are registered trademarks of **SpeedX** Pty Ltd. Other copyright and trademarks are the property of the respective owners. **SpeedX** Pty. Ltd. products may be covered by one or more local or foreign patents. Visit [www.plexpcr.com/patents](http://www.plexpcr.com/patents) for comprehensive patent information.

**Australia - SpeedX Pty. Ltd.**

+61 (0)2 9209 4170

sales@speedx.com.au

Suite 102, 4 Cornwallis Street,  
Eveleigh NSW 2015 Australia

Find out more [plexpcr.com](http://plexpcr.com)

